Videos

An Expert Explains the Enhertu Approval in HER2-Low and -Ultralow Breast Cancer

February 12th 2025, 2:00pm

Video

Dr. Debu Tripathy discusses the FDA approval of Enhertu in unresectable or metastatic hormone receptor HR+, HER2-low or -ultralow breast cancer.

Breaking Down The Importance of Targeted Therapies in Colorectal Cancer Care

February 11th 2025, 8:00pm

Video

Dr. Suneel Kamath discusses the ALASCCA study in colorectal cancer and highlighted the importance of next-generation sequencing and testing.

Explaining KRAS Mutations For Patients With Colorectal Cancer

February 11th 2025, 5:00pm

Video

Dr. Marwan G. Fakih explains that KRAS mutations, found in 45% of patients with colorectal cancer, include the rare KRAS G12C mutation, leading to Lumakras approval.

Personalized Kidney Cancer Vaccine May Help Prevent Future Relapse

February 11th 2025, 4:00pm

Video

In a clinical trial, patients treated with a kidney cancer vaccine remained cancer-free after a median of nearly three years.

The Importance of Utilizing Support Networks Following a Cancer Diagnosis

February 10th 2025, 10:00pm

Video

Dr. John Oertle discusses the key benefits to come from patients with cancer connecting with support networks, advocacy groups and resources.

An Expert Breaks Down What DPD Is and Labeling Updates From The FDA

February 10th 2025, 5:00pm

Video

Dr. Gabriel A. Brooks discusses the recent FDA product labeling update for Xeloda and 5-FU which aims to highlight risks associated with DPD deficiency.

Impact of PV on Lifestyle

February 5th 2025, 1:00pm

Video

A panelist discusses how polycythemia vera (PV) impacts daily life and lifestyle management, including beneficial changes patients can make, available support resources and educational materials while offering guidance for living with the condition.

Circulating Tumor DNA May Have Prognostic Value in Kidney Cancer

February 4th 2025, 10:00pm

Video

Dr. Alan Tan spoke with CURE® about what patients with kidney cancer and providers who treat it may be able to learn from ctDNA.

Cabometyx Demonstrates PFS Benefit Versus Placebo in GI-NETs

February 3rd 2025, 2:00pm

Video

Dr. Jonathan R. Strosberg, discussed results of the CABINET trial evaluating Cabometyx versus placebo in advanced gastrointestinal NETs.

How Do Molecular Factors Impact Response to Immunotherapy in Kidney Cancer?

January 30th 2025, 4:00pm

Video

Dr. David A. Braun delved into the molecular factors which drive exceptional responses to immunotherapy in metastatic clear cell renal cell carcinoma.